The effect of Saccharomyces bulardii in the eradication of Helicobacter pylori

The effect of Saccharomyces bulardii as an adjunctive therapy in the eradication of Helicobacter pylori

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221025056290N1

Enrollment

152

Registered

2022-11-03

Start date

2022-11-05

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori disease. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Intervention group: For fourteen days, he was treated with a four-drug regimen (pantaprazole 40 mg twice a day + amoxicillin 1 gram twice a day + clarithromycin 500 mg twice a day + bi

Eligibility

Sex/Gender

All

Age

19 Years to No maximum

Inclusion criteria

Inclusion criteria: People with Helicobacter pylori infection

Exclusion criteria

Exclusion criteria: History of systematic and standardized eradication treatment Kidney failure Taking antibiotics in the last month The person is pregnant and breastfeeding history of neurological disease Weakness in the immune system or taking immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication. Timepoint: After one month of the last dose of antibiotics, and the patients have not taken PPI drugs for at least two week. Method of measurement: Fecal antigen test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Kashanian

Kashan University of Medical Sciences

vhd2369@gmail.com+98 31 5541 0386

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026